It can take 10-15 years to develop a new medicine at an estimated cost of £1.2bn
At the Medicines Discovery Catapult we aim to help UK SME biotechs, academics and innovators have access to the laboratory facilities, knowledge, data, technologies and networks they need to be able to progress their programmes of medicines research and development. Our objective is to work collaboratively as part of a Syndicate to bring new proven therapies to patients faster and more cost-effectively.
Latest News
A new initiative to revitalise drug discovery in psychiatric disease: the Psychiatry Consortium launches first call for proposals
Today (3rd October 2019) the Psychiatry Consortium announces its first call for projects that focus on the identification of novel drug targets to address the
Medicines Discovery Catapult and Cystic Fibrosis Trust join forces to drive drug-discovery and address urgent unmet need
Cystic Fibrosis Syndicate in Antimicrobial Resistance launches Medicines Discovery Catapult has joined forces with the Cystic Fibrosis Trust to form the Cystic Fibrosis (CF) Syndicate in Antimicrobial Resistance (AMR).
Medicines Discovery Catapult, MQ: Transforming mental health and Alzheimer’s Research UK, announce strategic collaboration
Psychiatry Consortium to address unmet patient needs Today (18th June 2019) Medicines Discovery Catapult, MQ: Transforming mental health and Alzheimer’s Research UK announce an innovative